Founded through the convergent vision of Fundación Ciencia & Vida and Venturance Alternative Assets, we combine capital, scientific depth, and operational expertise to help founders turn breakthrough science into scalable businesses.
About Zentynel
Founded through the convergent vision of Fundación Ciencia & Vida and Venturance Alternative Assets, we combine capital, scientific depth, and operational expertise to help founders turn breakthrough science into scalable businesses.
The Zentynel Fund is led by a group of General Partners with deep expertise in science, entrepreneurship, and investment.
Bernardita has more than thirty years of experience in regulatory affairs and intellectual property in biomedical companies. She is president and co-founder of Fundación Ciencia y Vida. She also serves on the boards of Fundación Chile, Universidad Andrés Bello, Comunidad Mujer and other organizations.
After more than four decades of investment and business development in the biotechnology industry, Pablo has developed many cutting-edge medical technologies, such as the hepatitis B vaccine. He co-founded Chiron Corporation in 1982, one of the industry’s early pioneers in genetic engineering. In 2005, his company was acquired by Novartis for $8.9 billion.
Solving pressing challenges with worldwide implications.
Improving health, sustainability, and economic development in Latin America.
Empowering founders, creating jobs, and strengthening communities.